RxDoctor Payments Data

Bernardo Malaga, MD

General Practice · Aibonito, PRNPI 1386600187

Payments from drug & device makers

$535in general payments, 2019–2025

Across 27 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$130
  • GSK$111
  • Novo Nordisk$86
  • Dexcom, Inc.$45
  • AstraZeneca$35
  • Exact Sciences$24
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$130
GSK6$111
Novo Nordisk4$86
Dexcom, Inc.2$45
AstraZeneca2$35
Exact Sciences1$24
Lilly USA, LLC1$21
Si-bone, Inc.1$20
AbbVie1$18
Bayer1$18
Amgen1$14
Athena Bioscience, LLC1$13

How this compares

$535 in reported general payments places this provider in the 75th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,787
Medicare patients
13
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$85,010
EliquisApixaban39$53,951
FarxigaDapagliflozin Propanediol25$32,343
JanuviaSitagliptin Phosphate17$16,488
XareltoRivaroxaban11$14,075
Spiriva RespimatTiotropium Bromide18$11,090
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,410
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$5,674
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,027
Gabapentin138$4,204
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,192
Atorvastatin Calcium384$3,454
Albuterol Sulfate HfaAlbuterol Sulfate124$3,372
SymbicortBudesonide/Formoterol Fumarate12$3,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$35$35,36037 claims
GSKTrelegy Ellipta, Anoro Ellipta$111$14,43722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Aibonito

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →